Blood levels of GDF15 protein may help in liver cancer risk of MASLD
High blood levels of the growth differentiation factor 15 (GDF15) protein are associated with an elevated risk of liver cancer and other liver-related complications among…
News
Livmarli sustains benefit for Alagille patients over 7 years: Trial data
Nearly all children with Alagille syndrome who received Mirum Pharmaceuticals’ Livmarli (maralixibat) for seven years as part of clinical studies continued to experience…
BJT-778 antibody therapy shows early promise in Hep D trial
Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…
Global Fatty Liver Day to raise awareness of ‘concealed epidemic’
Global Fatty Liver Day, this year falling on June 13, is an annual effort to raise awareness about metabolic dysfunction-associated steatotic liver disease…
Seladelpar still eases itch, liver damage after 2 years: PBC trial
Two years of treatment with seladelpar, Gilead Sciences’ oral candidate, safely results in rapid and sustained reductions in itching and liver damage markers for…
Intrahepatic cholestasis of pregnancy risks mothers, newborns
Pregnant women with intrahepatic cholestasis of pregnancy (ICP) have an increased risk of other pregnancy-related problems, including gestational diabetes and preeclampsia, or sudden high…
Elafibranor, now Iqirvo, wins FDA accelerated approval for PBC
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).
In NASH, VK2809 treatment reduces liver fat, fibrosis: Phase 2b trial
One year of treatment with Viking Therapeutics’ candidate VK2809 safely and effectively reduces liver fat content, damage, and scarring in adults with nonalcoholic steatohepatitis…
Holomedicine aids liver transplant for girl with biliary atresia
An imaging technique called holomedicine helped surgeons in Singapore make sure they removed a part of a liver from a living adult donor that was…
Tobevibart, elebsiran can suppress hepatitis D virus: Phase 2 data
Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis D virus (HDV) levels and…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say